Hanyi He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanyi He has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Chenlong You
Zhejiang Cancer Hospital 2 , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
11 shared publications - Chunkai Zhang
Zhejiang Cancer Hospital 2 , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
11 shared publications - Dade Rong
University of Macau 1 Faculty of Health Sciences, Ministry of Education Frontiers Science Center for Precision Oncology Macau, China
11 shared publications - Dan Zu
Zhejiang Cancer Hospital 2 , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
11 shared publications - Haidong Liu
Zhejiang Cancer Hospital 2 , Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
11 shared publications - Han-Ming Shen
Faculty of Health Sciences, Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macau, China
11 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S2 demonstrates that PARG inhibition synergizes with fluoropyrimidines.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S2 demonstrates that PARG inhibition synergizes with fluoropyrimidines.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S1 shows PARG upregulation, independent prognostic value, and PARG inhibitor characterization in GC.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S1 shows PARG upregulation, independent prognostic value, and PARG inhibitor characterization in GC.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S3 confirms that combining PARG inhibitor with 5-FU does not cause significant body weight loss or major organ toxicity in PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S3 confirms that combining PARG inhibitor with 5-FU does not cause significant body weight loss or major organ toxicity in PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S4 shows that capecitabine plus PARG inhibitor treatment is well tolerated in PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S4 shows that capecitabine plus PARG inhibitor treatment is well tolerated in PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S5 shows that PARG deficiency or inhibition exacerbates 5-FU-induced DNA damage.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S5 shows that PARG deficiency or inhibition exacerbates 5-FU-induced DNA damage.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S6 demonstrates that PARG deficiency reduces RAD51AP1 localization to DNA damage sites and promotes 5-FU-induced genomic instability.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S6 demonstrates that PARG deficiency reduces RAD51AP1 localization to DNA damage sites and promotes 5-FU-induced genomic instability.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S7 provides biochemical evidence of direct PARG–RAD51AP1 interaction and PAR-dependent ubiquitination.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S7 provides biochemical evidence of direct PARG–RAD51AP1 interaction and PAR-dependent ubiquitination.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S9 confirms RAD51AP1 upregulation and positive correlation with PARG in GC tissues.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S9 confirms RAD51AP1 upregulation and positive correlation with PARG in GC tissues.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S8 shows RAD51AP1 overexpression restores chemoresistance in PARG-deficient xenografts without toxicity.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Fig. S8 shows RAD51AP1 overexpression restores chemoresistance in PARG-deficient xenografts without toxicity.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Supplementary Tables S1, S2 and S3 list the plasmids, sgRNA/siRNA sequences, and qPCR primers used in this study, respectively.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from PARG Governs a PARylation–Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination–Mediated Chemoresistance
Supplementary Tables S1, S2 and S3 list the plasmids, sgRNA/siRNA sequences, and qPCR primers used in this study, respectively.